Osteomyelitis is an acute or chronic inflammation of the bone due to an infection resulting from hematogenous spread, contiguous spread from soft tissues and joints to bone, or direct inoculation into bone from surgery or trauma.
The infection is generally due to a single microorganism but polymicrobial infections may also occur. Staphylococcus aureus is a major cause of infection.
Signs and symptoms include fever; inflammatory findings of erythema, warmth, pain and swelling over the involved area; draining sinus tracts over affected bone; limited movement of affected extremity; pain in the chest, back, abdomen or leg, and tenderness over involved vertebrae in patients with vertebral osteomyelitis; anorexia, vomiting and malaise.
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.